

REGIONAL MULTI-STAKEHOLDER ROUNDTABLE

ACCELERATING PATIENT ENGAGEMENT FOR MORE RESILIENT HEALTH SYSTEMS

23 Nov 2020
6PM* - 8.30PM SGT
24 Nov 2020
6PM* - 8PM SGT
(via Zoom)

Hosted by CoRE in partnership with Rainbow Across Borders, Milken Institute, Patient Focused Medicines Development and Singhealth Duke-NUS Global Health Institute



11/23日の会議終了時に
撮影されたものです。



一般社団法人
PPI JAPAN

General Incorporated Association


PPI JAPAN

Satoshi Miki, a Board member of PPI JAPAN

Nov. 23, 2020


at the CoRE Roundtable


次ページ以降の資料は日本語の既存公開資料に基づき、スピーカーが翻訳して紹介している情報を含むと共に、公開資料の紹介は省略しております。



PPI: Patient & Public Involvement

In the US and in Canada,
the “Involvement” is included
into the “Engagement”






PPI JAPAN / Greeting Message



**Dr. Tatsuya KONDO,
Chief Executive Officer
of PPI JAPAN**

- We promote mutual understanding and collaboration between patient groups, patient support groups, public, and industry-government-academia, who are all essential stakeholders in medicine development.
- We enable the development of polite communication while deeply understanding the needs of all stakeholders.



PPI JAPAN / Mid - Long Term Plan

- 1) Strive to develop human resources through the provision of learning programs
- 2) Promote social awareness and cooperation, develop coordination efforts among related parties and develop related materials
- 3) Share knowledge and experiences gained from Japan's PPI activities internationally and disseminate information to realize a fulfilling medical care system



PPI JAPAN: Our history and present & future

- Why not having a similar platform of **EUPATI**(**European **Patients' **Academy on **Therapeutic **Innovation****) in Japan was the initial idea.******
- "**Patient and Public Involvement (PPI) Consortium in Japan**" was established in July 2019.
- This consortium advanced to the legal entity as "**General Incorporated Association PPI JAPAN**" in Nov. 2019. Then it has become **the first EUPATI national platform outside Europe as from April 2020.**
- Simply copying and pasting EUPATI was not an option. The background and relationship of patients and medicine as well as cultural aspects in Japan are so different from those in Europe.
- Fully utilize the **best practice of patient engagement initiatives** in the world; like EUPATI **for the benefit to the patients and public in Japan.**



Accessibility Collaborate Donate Contact Login English ▾

About us Resources National Platforms News Projects **Training** **Toolbox**

EUPATI: Patient Engagement Through Education

Providing patients with accessible and reliable information and training on medicines research and development and other therapeutic innovations. A patient-led partnership working across stakeholders to enhance patient engagement.


[What is EUPATI?](#)

Training

EUPATI offers face-to-face and online courses on medicines' research & development and patient

Toolbox

The Toolbox is an online library on the A-Z of medicines research and development and patient



Japan is one of the EUPATI National Platforms



EUPATI National Platforms:

[Austria](#)

[Finland](#)

[Italy](#)

[Netherlands](#)

[Slovakia](#)

[Turkey](#)

[Belgium](#)

[France](#)

[Japan](#)

[Norway](#)

[Spain](#)

[United Kingdom](#)

[Cyprus](#)

[Germany](#)

[Luxembourg](#)

[Poland](#)

[Switzerland](#)

[Scotland](#)

[Denmark](#)

[Ireland](#)

[Malta](#)

[Portugal](#)


[Sweden](#)

[Back to the top](#) ^

EUPATI



[Contact](#) [Donate](#) [Collaborate](#) [Sustaining Partners](#) [National Platforms](#)



PPI GUIDE BOOK & leaflet by AMED


(Japan Agency for Medical Research and Development)


PPI is positioned as an essential concept for promoting research and development in medical care.

"Efforts for cooperation with patients and educational activities for the public" was indicated as an important item.

It is clearly stated that engagement of participants and patients from the planning stage need to be promoted in conducting clinical research and clinical trials.

AMED released the PPI Guidebook on its website in April 2019.





Some stakeholders actions and trends on PPI in Japan


PMDA (Pharmaceutical & Medical Device Agency):

- The "**Patient Engagement Study WG**" was organized within PMDA in May 2019.
- It aims to create **guidance on the public communication for patients** as well as **the relationship between patient activity and PMDA as measures for patient engagement and cooperation with patients.**


JPMA (Japan Pharmaceutical Manufacturing Association):

- Started its activity of "Patient Centricity" since 2016.
- In June 2018, "Pharmaceutical development utilizing patient's voice - Patient Centricity by pharmaceutical companies" was published.
- In Sep. 2019, "**Guidebook** for pharmaceutical companies to carry out activities based on Patient Centricity - Drug Development utilizing patient's voice" and the summary report on "Drug Development utilizing patient's voice: **Communication guidebook** for pharmaceutical companies to promote activities with patient groups based on Patient Centricity" were published.

As triggered by the activities of the Japanese Society for Cancer Treatment, PPI-related activities have started at academic conferences related to lethal diseases.



一般社団法人
PPI JAPAN



一般社団法人PPI JAPAN